Education
About Us
Working with TipRanks
Follow Us
Xenetic Biosciences (XBIO)
NASDAQ:XBIO
Total Valuation
Xenetic Biosciences has a market cap or net worth of $7.74M. The enterprise value is -$2.67M.
Market Cap$7.74M
Enterprise Value-$2.67M
Share Statistics
Xenetic Biosciences has 2,291,056 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,291,056
Owned by Insiders―
Owned by Institutions0.72%
Financial Efficiency
Xenetic Biosciences’s return on equity (ROE) is -0.36 and return on invested capital (ROIC) is -38.33%.
Return on Equity (ROE)-0.36
Return on Assets (ROA)-0.32
Return on Invested Capital (ROIC)-38.33%
Return on Capital Employed (ROCE)-0.38
Revenue Per Employee1.49M
Profits Per Employee-1.34M
Employee Count2
Asset Turnover0.36
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Xenetic Biosciences is ―. Xenetic Biosciences’s PEG ratio is 0.04.
PE Ratio―
PS Ratio1.24
PB Ratio0.50
Price to Fair Value0.50
Price to FCF-1.61
Price to Operating Cash Flow-3.39
PEG Ratio0.04
Income Statement
In the last 12 months, Xenetic Biosciences had revenue of 2.98M and earned -2.68M in profits. Earnings per share was -1.58.
Revenue2.98M
Gross Profit0.00
Operating Income-2.83M
Pretax Income-2.68M
Net Income-2.68M
EBITDA-2.83M
Earnings Per Share (EPS)-1.58
Cash Flow
In the last 12 months, operating cash flow was -2.29M and capital expenditures -1.00, giving a free cash flow of -2.29M billion.
Operating Cash Flow-2.29M
Free Cash Flow-2.29M
Free Cash Flow per Share-1.00
Dividends & Yields
Xenetic Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.09
52-Week Price Change-2.31%
50-Day Moving Average2.36
200-Day Moving Average3.00
Relative Strength Index (RSI)75.51
Average Volume (3m)1.70M
Important Dates
Xenetic Biosciences upcoming earnings date is Mar 25, 2026, TBA (Confirmed).
Last Earnings DateNov 14, 2025
Next Earnings DateMar 25, 2026
Ex-Dividend Date―
Financial Position
Xenetic Biosciences as a current ratio of 8.32, with Debt / Equity ratio of 0.00%
Current Ratio8.32
Quick Ratio8.32
Debt to Market Cap0.00
Net Debt to EBITDA2.78
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Xenetic Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Xenetic Biosciences EV to EBITDA ratio is 1.48, with an EV/FCF ratio of 1.83.
EV to Sales-1.41
EV to EBITDA1.48
EV to Free Cash Flow1.83
EV to Operating Cash Flow1.83
Balance Sheet
Xenetic Biosciences has $7.88M in cash and marketable securities with $0.00 in debt, giving a net cash position of $7.88M billion.
Cash & Marketable Securities$7.88M
Total Debt$0.00
Net Cash$7.88M
Net Cash Per Share$3.44
Tangible Book Value Per Share$4.35
Margins
Gross margin is 74.25%, with operating margin of -95.23%, and net profit margin of -90.07%.
Gross Margin74.25%
Operating Margin-95.23%
Pretax Margin-90.07%
Net Profit Margin-90.07%
EBITDA Margin-95.23%
EBIT Margin-95.23%
Analyst Forecast
The average price target for Xenetic Biosciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast13.30%
EPS Growth Forecast22.70%